<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341989</url>
  </required_header>
  <id_info>
    <org_study_id>2014/2012</org_study_id>
    <secondary_id>2014-004075-23</secondary_id>
    <nct_id>NCT02341989</nct_id>
  </id_info>
  <brief_title>Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer</brief_title>
  <acronym>SWENOTECA-ABC</acronym>
  <official_title>A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norrlands University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One course of adjuvant carboplatin AUC7 is considered internationally to be a standard&#xD;
      treatment option in clinical stage I seminoma, regardless of risk factors. Treatment is based&#xD;
      on a large, randomized phase III study comparing adjuvant carboplatin with adjuvant&#xD;
      radiotherapy. This study was done without registering data on possible risk factor for&#xD;
      relapse. The relapse rate following carboplatin was in this study estimated to be 5.3 %. Data&#xD;
      from a prospective, risk-adapted Spanish study showed that patients without risk factors had&#xD;
      a very low risk of relapse, even without adjuvant treatment. This result is also confirmed by&#xD;
      a recent analysis of SWENOTECA VII data, showing that this group of patients has a risk of&#xD;
      relapse of less than 5 % without adjuvant treatment.&#xD;
&#xD;
      Combined data from SWENOTECA V and VII studies indicate a high risk of relapse in patients&#xD;
      with one or two risk factors (tumor 4 cm, stromal invasion of rete testis) treated with one&#xD;
      course of adjuvant carboplatin. The relapse rate in this group of patients was 9.4 %,&#xD;
      indicating a very modest effect of one course of adjuvant carboplatin. If adjuvant&#xD;
      chemotherapy is the preferred treatment strategy, more potent chemotherapy regimens should be&#xD;
      explored in this patient group. The results from SWENOTECA III/VI studies with one course of&#xD;
      cisplatin-based adjuvant chemotherapy in clinical stage I nonseminoma, show a very low rate&#xD;
      of relapse. As seminoma is even more chemosensitive than nonseminoma the relapse rate&#xD;
      following one course of adjuvant BEP is expected to be very low, close to 1 %.&#xD;
&#xD;
      The overall aim is to investigate whether one course of adjuvant BEP have a lower relapse&#xD;
      rate than one course of adjuvant carboplatin AUC7. In addition, it will be investigated if&#xD;
      there is a difference in health related quality of life as well as acute and long-term&#xD;
      toxicities from treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Short term overall survival is, regardless of treatment allocation, expected to be very close&#xD;
      to 100 %. The primary outcome is relapse rate. The power of the study depends on the number&#xD;
      of observed relapses. If the relapse rate in the adjuvant carboplatin group, the reference&#xD;
      group, is lower than the anticipated 9 %, we need to include more patients to the study.&#xD;
      Based on all previous published material on adjuvant treatment in clinical stage I seminoma&#xD;
      it is not possible to precisely estimate the correct relapse rate until the median follow-up&#xD;
      is four years. Consequently, we will estimate the relapse rate in the reference group close&#xD;
      to the end of accrual. If the estimated relapse rate, and thus the number of relapses, is&#xD;
      lower than the anticipated we will increase the sample size to make sure that the study meets&#xD;
      the minimum required number of relapses in the reference group. A possible inclusion of more&#xD;
      study participants does not compromise the Type I error rate of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 8, 2015</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Testicular Neoplasms</condition>
  <condition>Seminoma</condition>
  <arm_group>
    <arm_group_label>Bleomycin-Etoposide-Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One course of adjuvant BEP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One course of adjuvant carboplatin AUC7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin Etoposide and Cisplatin</intervention_name>
    <arm_group_label>Bleomycin-Etoposide-Cisplatin</arm_group_label>
    <other_name>BEP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Carboplatin</arm_group_label>
    <other_name>Carboplatin AUC7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of unilateral seminoma testicular cancer, evaluating both size&#xD;
             of tumor and invasion of the rete testis&#xD;
&#xD;
          -  Clinical stage I&#xD;
&#xD;
          -  Tumor size over 4 cm and/or stromal invasion of the rete testis by tumor cells&#xD;
&#xD;
          -  Normal value of alpha-fetoprotein (AFP) before orchiectomy. A stable, slightly&#xD;
             elevated AFP as a normal value may be permitted.&#xD;
&#xD;
          -  Age ≥ 18 years and &lt; 60 years&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
        Serum aspartate transaminase (ALT) ≤ 1.5 x upper limit of normal (ULN). Total serum&#xD;
        bilirubin ≤ 1.5 x ULN Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L&#xD;
        Creatinine clearance &gt; 50 ml/min (eGFR) All fertile patients should use safe contraception&#xD;
        Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of metastatic disease evaluated by CT thorax, abdomen and pelvis. Patients in&#xD;
             need of restaging (see SWENOTECA IX) should not be included&#xD;
&#xD;
          -  Prior diagnosis of testicular cancer&#xD;
&#xD;
          -  Chronic pulmonary disorders giving a high risk of bleomycin induced toxicity (for&#xD;
             example chronic obstructive pulmonary disease or lung fibrosis)&#xD;
&#xD;
          -  Cancer other than seminoma testicular cancer&#xD;
&#xD;
          -  Known hypersensitivity or contraindications for the study drugs&#xD;
&#xD;
          -  Serious concomitant systemic disorders (for example active infection, unstable&#xD;
             cardiovascular disease) that in the opinion of the investigator would compromise the&#xD;
             patient's ability to complete the study or interfere with the evaluation of the&#xD;
             efficacy and safety of the study treatment&#xD;
&#xD;
          -  Medical, social, psychological conditions that could prevent adequate information and&#xD;
             follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olof Ståhl, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torgrim Tandstad, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Olavs University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institutt for kreftforskning og molekylær medisin, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 14, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy, adjuvant</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seminoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

